Viral transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in gene therapy

• Published in: Postȩpy higieny i medycyny doświadczalnej Vol. 69; pp. 1411 - 1422
• Main Authors: Wędrowska, Ewelina, Wandtke, Tomasz, Dyczek, Andrzej, Woźniak, Joanna
• Format: Journal Article
• Language: Polish
• Published: Poland 31-12-2015
• Subjects: Adenoviridae; Apoptosis - genetics; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung - therapy; Cell Death; Genetic Therapy; Genetic Vectors; Humans; Membrane Glycoproteins - metabolism; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 1732-2693

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces carcinoma cell death through the extrinsic pathway of apoptosis. Preclinical trials of gene therapy have been conducted using viral transfer of the TRAIL transgene into prostate, bladder, breast, kidney, liver, non-small cell lung cancer and also glioblastoma cells. Experiments in vitro demonstrated the extensive apoptosis of target cells as well as frequent disease regression or remission. TRAIL transfer did not show any side effects, opposite to chemotherapy. Encouraging results of TRAIL-related gene therapy were observed in rheumatoid arthritis and type 1 diabetes. Adenoviral vectors (AdV) encoding TRAIL are the most promising tool in anti-tumor therapy. They have undergone numerous modifications by increasing transfection efficiency and transgene expression in target cells. However, only one clinical phase I trial has been performed. AdV encoding the TRAIL transgene caused local inflammation and apoptosis in patients with prostate cancer.